Hualan Vaccine's 2026 interim report shows net profit of 36.4432 million yuan

Earnings
โดย Jiemian·CN·Read original
Summary · why it matters

Hualan Vaccine released its 2026 interim report. The company's total operating revenue was 44.3853 million yuan, down 25.98% year-on-year, and net profit attributable to the parent company was 36.4432 million yuan. Net cash inflow from operating activities was 166 million yuan, the asset-liability ratio was 16.15%, the gross margin was 47.83%, ROE was 0.69%, and diluted earnings per share was 0.06 yuan. The company had 22,900 shareholders, and the top ten shareholders held 83.34% of the shares.

Impact on stocks 1

Others▼ · 1 stocks
© 2026 MarketDXNews